Publications by authors named "R Del Rio-Villegas"
Article Synopsis
- * Researchers analyzed data from over 1500 patients and found that women reported higher sleepiness on the Epworth Sleepiness Scale compared to men, with specific age-related trends observed in different patient groups.
- * Notably, in women with narcoleptic conditions, an increase in daytime sleepiness was linked to age, while weight gain appeared later, suggesting a complex relationship that warrants further research for targeted treatment approaches.
Background: Narcolepsy type 1 is caused by severe loss or lack of brain orexin neuropeptides.
Methods: We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1. Patients with confirmed narcolepsy type 1 according to clinical criteria were randomly assigned to receive twice-daily oral TAK-994 (30 mg, 90 mg, or 180 mg) or placebo.
Introduction: Type 1 narcolepsy is a disabling disease that requires continuous treatment, which is not always effective. Pitolisant is a new drug with a different mechanism of action that offers a new treatment option. The objective of the study was to analyse the effectiveness and safety of pitolisant in patients with type 1 narcolepsy that did not respond to or tolerate previous standard treatments.
View Article and Find Full Text PDFPurpose: Narcolepsy type-1 (NT1) is a rare chronic neurological sleep disorder with excessive daytime sleepiness (EDS) as usual first and cataplexy as pathognomonic symptom. Shortening the NT1 diagnostic delay is the key to reduce disease burden and related low quality of life. Here we investigated the changes of diagnostic delay over the diagnostic years (1990-2018) and the factors associated with the delay in Europe.
View Article and Find Full Text PDF